Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy. In this randomised controlled trial we investigated whether intercalated erlotinib with chemotherapy was superi...

Full description

Bibliographic Details
Main Authors: Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
Format: Article
Language:English
Published: European Respiratory Society 2022-10-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/8/4/00239-2022.full

Internet

http://openres.ersjournals.com/content/8/4/00239-2022.full

Similar Items